FHIR IG analytics| Package | hl7.org.nz.fhir.ig.cca |
| Resource Type | PlanDefinition |
| Id | PlanDefinition-ColoRectal.json |
| FHIR Version | R4 |
| Source | https://build.fhir.org/ig/HL7NZ/cca/PlanDefinition-ColoRectal.html |
| URL | http://hl7.org.nz/fhir/ig/cca/PlanDefinition/ColoRectal |
| Version | 0.1.0 |
| Status | active |
| Date | 2020-06-29T20:14:18.417+12:00 |
| Title | Colorectal Adjuvant FOLFOX (a7) |
| Realm | nz |
| Authority | hl7 |
| Description | A drug treatment regimen for Colorectal cancer. Plan is still under review. |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
FHIR
FHIRsmith{
"resourceType": "PlanDefinition",
"id": "ColoRectal",
"meta": {
"profile": [
"http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition"
]
},
"text": {
"status": "additional",
"div": "<!-- snip (see above) -->"
},
"contained": [
{
"resourceType": "ActivityDefinition",
"id": "ActTragacanth",
"meta": {
"profile": [
"http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"
]
},
"text": {
"status": "additional",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Tragacanth administration, 3mg over 3 hours by continuous IV infusion</div>"
},
"status": "draft",
"productCodeableConcept": {
"coding": [
{
"system": "https://nzulm.org.nz/nzmt",
"code": "10711851000116105",
"display": "Tragacanth"
}
]
},
"dosage": [
{
"text": "3 mg over 3 hours by IV infusion",
"route": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "180177004",
"display": "continuous intravenous infusion"
}
]
},
"doseAndRate": [
{
"doseQuantity": {
"value": 3,
"system": "http://unitsofmeasure.org",
"code": "mg"
},
"rateQuantity": {
"value": 3,
"system": "http://unitsofmeasure.org",
"code": "h"
}
}
]
}
]
}
],
"extension": [
{
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
"valueMarkdown": "Only for women"
},
{
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer",
"valueMarkdown": "Developed with the best of intentions."
},
{
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-regimen-type",
"valueCodeableConcept": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "dummy"
}
],
"text": "Folfox"
}
},
{
"extension": [
{
"url": "factor",
"valueCodeableConcept": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "TOUPDATE-SUPPORT4",
"display": "Diarrhoea risk"
}
]
}
},
{
"url": "value",
"valueCodeableConcept": {
"text": "low"
}
}
],
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
},
{
"extension": [
{
"url": "factor",
"valueCodeableConcept": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "TOUPDATE-SUPPORT8",
"display": "AntiFungal Prophylaxis"
}
]
}
},
{
"url": "value",
"valueCodeableConcept": {
"text": "low"
}
}
],
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
},
{
"extension": [
{
"url": "factor",
"valueCodeableConcept": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "TOUPDATE-SUPPORT2",
"display": "Hypersensitivity / Infusion related reaction ris"
}
]
}
},
{
"url": "value",
"valueCodeableConcept": {
"text": "low"
}
}
],
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
}
],
"url": "http://hl7.org.nz/fhir/ig/cca/PlanDefinition/ColoRectal",
"version": "0.1.0",
"title": "Colorectal Adjuvant FOLFOX (a7)",
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/plan-definition-type",
"code": "clinical-protocol"
}
]
},
"status": "active",
"_status": {
"extension": [
{
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-additional-plan-status",
"valueCode": "review"
}
]
},
"experimental": false,
"date": "2020-06-29T20:14:18.417+12:00",
"publisher": "Te Aho o Te Kahu, Cancer Control Agency",
"description": "A drug treatment regimen for Colorectal cancer. Plan is still under review.",
"useContext": [
{
"code": {
"system": "http://terminology.hl7.org/CodeSystem/usage-context-type",
"code": "focus"
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "781382000",
"display": "Colorectal cancer"
}
]
}
}
],
"relatedArtifact": [
{
"type": "citation",
"display": "test",
"url": "http://www.ncbi.nlm.nih.gov/pubmed/23434",
"document": {
"url": "http://www.ncbi.nlm.nih.gov/pubmed/23434"
}
},
{
"type": "citation",
"display": "test2",
"url": "http://www.ncbi.nlm.nih.gov/pubmed/34324",
"document": {
"url": "http://www.ncbi.nlm.nih.gov/pubmed/34324"
}
}
],
"action": [
{
"extension": [
{
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
"valueMarkdown": "Ensure not pregnant before starting"
}
],
"title": "This is the only cycle in the regimen.",
"description": "Administration of Cabergoline and Tragacanth. Cycle length 14 days",
"timingTiming": {
"repeat": {
"count": 1,
"duration": 14,
"durationUnit": "d"
}
},
"selectionBehavior": "all",
"action": [
{
"extension": [
{
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
"valueMarkdown": "Keep a close eye for side effects"
},
{
"extension": [
{
"url": "day",
"valueInteger": 1
},
{
"url": "instructions",
"valueString": "Specific instructions for the day 1 administration"
}
],
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
},
{
"extension": [
{
"url": "day",
"valueInteger": 4
},
{
"url": "instructions",
"valueString": "Specific instructions for the day 4 administration"
}
],
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
}
],
"description": "2mg of Cabergoline daily on days 1 and 4 by IV Infusion over 20 minutes",
"definitionCanonical": "#act-cabergoline"
},
{
"extension": [
{
"extension": [
{
"url": "day",
"valueInteger": 2
},
{
"url": "instructions",
"valueString": "Specific instructions for the day 2 administration"
}
],
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
},
{
"extension": [
{
"url": "day",
"valueInteger": 3
},
{
"url": "instructions",
"valueString": "Specific instructions for the day 3 administration"
}
],
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
},
{
"extension": [
{
"url": "day",
"valueInteger": 4
},
{
"url": "instructions",
"valueString": "Specific instructions for the day 4 administration"
}
],
"url": "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
}
],
"description": "3mg of Tragacanth daily on days 2,3 and 4 by IV Infusion over 3 hours",
"definitionCanonical": "#act-tragacanth"
}
]
}
]
}